N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

@article{Lai2012NacetylcysteineRD,
  title={N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.},
  author={Zhi-wei Lai and Robert Hanczko and Eduardo Bonilla and Tiffany N. Caza and Brandon Clair and Adam Bartos and Gabriella Mikl{\'o}ssy and John R. Jimah and Edward J. Doherty and Hajra Ismail Tily and Lisa Francis and Ricardo J Garcia and Maha Dawood and Jianghong Yu and Irene Ramos and Ioana Coman and Stephen V Faraone and Paul E. Phillips and Andr{\'a}s Perl},
  journal={Arthritis and rheumatism},
  year={2012},
  volume={64 9},
  pages={2937-46}
}
OBJECTIVE Systemic lupus erythematosus (SLE) patients exhibit T cell dysfunction, which can be regulated through mitochondrial transmembrane potential (Δψm) and mammalian target of rapamycin (mTOR) by glutathione (GSH). This randomized, double-blind, placebo-controlled study was undertaken to examine the safety, tolerance, and efficacy of the GSH precursor N-acetylcysteine (NAC). METHODS A total of 36 SLE patients received either daily placebo or 1.2 gm, 2.4 gm, or 4.8 gm of NAC. Disease… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 6 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review

Therapeutics and clinical risk management • 2014
View 17 Excerpts
Highly Influenced

T-cell metabolism in autoimmune disease

Arthritis research & therapy • 2015
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…